ZSAN logo

Zosano Pharma (ZSAN) Stock

Profile

Full Name:

Zosano Pharma Corporation

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 January 2015

Indexes:

Not included

Website:

http://www.zosanopharma.com

Description:

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$785.00 K(+250.45% YoY)

Annual EPS

-$9.45(+44.90% YoY)

PE Ratio

-

Annual ROE

-74.36%

Annual Debt To Equity

0.15

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 10, 2021

Recent annual earnings:

Mar 11, 2021
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 12, 2022

Analyst ratings

Recent major analysts updates

No data about analysts updates

Screeners with ZSAN included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$233.40
ZSAN price is currently at an all-time high

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Net Income 3-Year Change

+15.37%
ZSAN annual net profit is up +15.37% over the past 3 years

Annual EPS 3-Year Change

+92.78%
ZSAN annual earnings per share is up +92.78% over the past 3 years

Annual Gross Profit

-$11.00 K
ZSAN annual gross profit is -$11.00 thousand

Annual Operating Profit

-$31.53 M
ZSAN annual operaing income is -$31.53 million

Annual Operating Profit 3-Year Change

+9.56%
ZSAN annual operaing income is up +9.56% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-74.36%
ZSAN annual return on equity is -74.36%

Annual ROA

-49.71%
ZSAN annual return on assets is -49.71%

Annual EBIT

-$29.74 M
ZSAN annual earnings before interest & taxes is -$29.74 million

Annual EBITDA

-$27.98 M
ZSAN annual earnings before interest, taxes, depreciation & amortization is -$27.98 million

Annual Interest Coverage Ratio

-157.33
ZSAN annual interest coverage ratio is -157.33

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Current Ratio

1.04
ZSAN annual current ratio is 1.04

Annual Total Assets

$48.39 M
ZSAN annual total assets is $48.39 million

Annual Current Assets

$11.61 M
ZSAN annual total current assets is $11.61 million

Annual Total Liabilities

$15.41 M
ZSAN annual total liabilities is $15.41 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+5.26%
ZSAN annual cash flow from operations is up +5.26% over the past 3 years

Annual CFI 3-Year Change

+71.77%
ZSAN annual cash flow from investing activities is up +71.77% over the past 3 years

Annual CFF 3-Year Change

-80.81%
ZSAN annual cash flow from financing activities is down -80.81% over the past 3 years

Annual CAPEX

$5.42 M
ZSAN annual capital expenditures is $5.42 million

Annual CAPEX 3-Year Change

-1.22%
ZSAN annual capital expenditures is down -1.22% over the past 3 years

Annual FCF

-$33.01 M
ZSAN annual free cash flow is -$33.01 million

Annual FCF 3-Year Change

+4.62%
ZSAN annual free cash flow is up +4.62% over the past 3 years

Institutional Ownership

Similar stocks

FAQ

  • What is the primary business of Zosano Pharma?
  • What is the ticker symbol for Zosano Pharma?
  • Does Zosano Pharma pay dividends?
  • What sector is Zosano Pharma in?
  • What industry is Zosano Pharma in?
  • What country is Zosano Pharma based in?
  • When did Zosano Pharma go public?
  • Is Zosano Pharma in the S&P 500?
  • Is Zosano Pharma in the NASDAQ 100?
  • Is Zosano Pharma in the Dow Jones?
  • When was Zosano Pharma's last earnings report?
  • When does Zosano Pharma report earnings?

What is the primary business of Zosano Pharma?

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

What is the ticker symbol for Zosano Pharma?

The ticker symbol for Zosano Pharma is NASDAQ:ZSAN

Does Zosano Pharma pay dividends?

No, Zosano Pharma does not pay dividends

What sector is Zosano Pharma in?

Zosano Pharma is in the Healthcare sector

What industry is Zosano Pharma in?

Zosano Pharma is in the Biotechnology industry

What country is Zosano Pharma based in?

Zosano Pharma is headquartered in United States

When did Zosano Pharma go public?

Zosano Pharma's initial public offering (IPO) was on 27 January 2015

Is Zosano Pharma in the S&P 500?

No, Zosano Pharma is not included in the S&P 500 index

Is Zosano Pharma in the NASDAQ 100?

No, Zosano Pharma is not included in the NASDAQ 100 index

Is Zosano Pharma in the Dow Jones?

No, Zosano Pharma is not included in the Dow Jones index

When was Zosano Pharma's last earnings report?

Zosano Pharma's most recent earnings report was on 10 November 2021

When does Zosano Pharma report earnings?

The date for Zosano Pharma's next earnings report has not been announced yet